Compare ClearPoint Neuro Inc (CLPT) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Dolby Laboratories, Inc. — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while Dolby Laboratories, Inc. trades at $61.82 (market cap $5.82B). The key difference: Dolby Laboratories, Inc. is far larger — about 13.1× ClearPoint Neuro Inc's market cap, and Dolby Laboratories, Inc. pays a 2.32% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | DLB | |
|---|---|---|
Market Cap | $444.14M | $5.82B |
Sector | Health | Industrials |
52-Week High | $29.60 | $75.62 |
52-Week Low | $8.66 | $48.51 |
Enterprise Value | $478.72M | $5.19B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
Dolby Laboratories (DLB) trades at $61.77, up 1.4% today, with a bullish technical trend and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $0.69 versus $0.67 expected. Revenue remains stable around $1.3 billion annually, with robust gross margins of 87.61%. Recent news highlights growth in Dolby Atmos and automotive licensing, though near-term revenue volatility persists.
DLB offers a compelling valuation with a P/E of 26.29 below the analyst target of $87.50, implying significant upside. Key risks include licensing deal timing and competitive pressures in audio-video tech. Institutional sentiment is positive, with 47% of analysts rating it a Buy, but investors should monitor execution on Q4 growth guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
